Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793716/0/en/Lexeo-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Highlights.html

Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease

Received clearance of LX2006 Clinical Trial Application (CTA) in Canada for the treatment of FA cardiomyopathy; activated first clinical trial site outside of the United States

Read more at globenewswire.com

Related news for (LXEO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.